SCHEMBL130659

SCHEMBL130659

[CH2]Cc1ccc(Cl)cc1Cl

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 5/20 0.60
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2C9 P11712 1/20 0.58
MAPK1 P28482 1/20 0.58
CYP2C19 P33261 1/20 0.58
CYP2A13 Q16696 1/20 0.48
TP53 P04637 1/20 0.48
HTT P42858 4/20 0.46
GGPS1 O95749 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
RAB9A P51151 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
PYCR1 P32322 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL398220 0.81 IDO1 (0.56) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL1802749 0.80 IDO1 (0.60) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL1547586 0.80 TP53 (0.48) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL11621292 0.79 IDO1 (0.65) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL2097653 0.79 IDO1 (0.65) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL165560 0.78 IDO1 (0.69) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL29984975 0.78 IDO1 (0.69) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL9455806 0.78 IDO1 (0.38) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL401356 0.78 IDO1 (0.52) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL283639 0.77 IDO1 (0.62) IDO1CYP1A2CYP3A4CYP2C9MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 802 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919854-B2 P2RX7 modulators in therapy CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2024-03-05 US claimed
CN-112867706-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2021-05-28 CN claimed
EP-3802489-A2 MASP-2 INHIBITORS AND METHODS OF USE Omeros Corporation (US) 2021-04-14 EP claimed
CN-112512520-A P2RX7 modulators in therapy 国家科学研究中心 2021-03-16 CN claimed
EP-3773557-A1 P2RX7 MODULATORS IN THERAPY Centre national de la recherche scientifique (FR) 2021-02-17 EP claimed
US-20210017131-A1 P2RX7 MODULATORS IN THERAPY JUNIA (FR) 2021-01-21 US claimed
WO-2020196767-A1 FOAMED MULTILAYER SHEET, UNFOAMED MULTILAYER SHEET, FUNGICIDE, AND RESIN COMPOSITION 大日本印刷株式会社 2020-10-01 WO claimed
US-20200215194-A1 APOPTOSIS INHIBITOR FORMULATIONS FOR PREVENTION OF HEARING LOSS SPIRAL THERAPEUTICS, INC. 2020-07-09 US claimed
CN-111362932-A Isothiazole oxadiazole amide derivatives and preparation method and application thereof 南开大学 2020-07-03 CN claimed
US-10561736-B1 Apoptosis inhibitor formulations for prevention of hearing loss SPIRAL THERAPEUTICS, INC. (US) 2020-02-18 US claimed
US-5976894-A FOR SCREENING BIOASSAYS TO DISCOVER BIOLOGICALLY ACTIVE MEMBERS PHARMACOPEIA, INC. (US) 1999-11-02 US claimed
US-5401766-A Hypotensive agents with vasodilation HOECHST AKTIENGESELLSCHAFT (DE) 1995-03-28 US claimed
EP-0328160-B1 Amino acid derivatives, process to prepare them, composition containing them and their use HOECHST AG (DE) 1994-05-04 EP claimed
US-5192783-A Fungicides for plants ROHM AND HAAS COMPANY (US) 1993-03-09 US claimed
EP-0378615-A4 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES 1992-04-08 EP claimed
EP-0378615-A1 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES COMPETITIVE TECHNOLOGIES INC. (US) 1990-07-25 EP claimed
EP-0046953-B1 AMINO ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1989-12-06 EP claimed
WO-1989011486-A1 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES UNIVERSITY PATENTS, INC. (US) 1989-11-30 WO claimed
EP-0328160-A1 Amino acid derivatives, process to prepare them, composition containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1989-08-16 EP claimed
EP-0278530-A2 Amino acid derivatives, process for their preparation, agents containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1988-08-17 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210017131-A1 P2RX7 MODULATORS IN THERAPY P2RX3, P2RX7, P2RX2 IDO1 1464/4885CYP1A2 931/4885CYP3A4 1084/4885
US-10561736-B1 Apoptosis inhibitor formulations for prevention of hearing loss APAF1, API5, CASP9 IDO1 2938/4885CYP1A2 4559/4885CYP3A4 4755/4885
US-11919854-B2 P2RX7 modulators in therapy P2RX7, P2RX2, P2RX1 IDO1 1389/4885CYP1A2 881/4885CYP3A4 929/4885
US-20200215194-A1 APOPTOSIS INHIBITOR FORMULATIONS FOR PREVENTION OF HEARING LOSS APAF1, API5, CASP9 IDO1 2938/4885CYP1A2 4559/4885CYP3A4 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.